ArticleInternational journal of Alzheimer's disease2012
Insulin receptor expression and activity in the brains of nondiabetic sporadic Alzheimer's disease cases.
Article in International journal of Alzheimer's disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Alzheimer's Disease as Type 3 Diabetes: Understanding the Link and Implications.International journal of molecular sciences · 2024Review
- The Connection between Chronic Liver Damage and Sporadic Alzheimer's Disease: Evidence and Insights from a Rat Model.Brain sciences · 2023Article
- Impaired insulin signalling and allostatic load in Alzheimer disease.Nature reviews. Neuroscience · 2022Review
- Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.Molecules (Basel, Switzerland) · 2020Review
- Diabetes and Alzheimer's Disease: A Link not as Simple as it Seems.Neurochemical research · 2019Review
- Current Strategies for Brain Drug Delivery.Theranostics · 2018Review
- Parahippocampal gyrus expression of endothelial and insulin receptor signaling pathway genes is modulated by Alzheimer's disease and normalized by treatment with anti-diabetic agents.PloS one · 2018 · on this mapArticle
- Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease.Yonsei medical journal · 2017Review
- Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?The Journal of experimental medicine · 2016Review
- Pancreatic regulation of glucose homeostasis.Experimental & molecular medicine · 2016Review
- Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
- The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2014Review
- Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs.Neurodegenerative disease management · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
We investigated the contents of the insulin receptor-beta subunit (IRβ) and [Tyr1162/1163]-phosphorylated IRβ as surrogate indices of total IR content and IR activation in postmortem hippocampal formation brain specimens from nondiabetic sporadic Alzheimer's disease (AD) cases. We found no significant changes in the brain contents of total IRβ or [Tyr1162/1163]-phosphorylated IRβ, suggesting normal IR content and activation in the brains of nondiabetic sporadic AD cases. Moreover, total IRβ and [Tyr1162/1163]-phosphorylated IRβ levels in the hippocampal formation are not correlated with the severity of amyloid or tau-neuropathology. Exploring the regulation of glycogen synthase kinase 3 (GSK3) α/β, key IR-signaling components, we observed significantly lower levels of total GSK3 α/β in brain specimens from nondiabetic AD cases, suggesting that impaired IR signaling mechanisms might contribute to the onset and/or progression of AD dementia. Outcomes from our study support the development of insulin-sensitizing therapeutic strategies to stimulate downstream IR signaling in nondiabetic AD cases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.